I.V Oxytocin administration
PreclinicalSmall molecule
I.V Oxytocin administration is one of 12 small molecule programs targeting Postpartum Hemorrhage. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Postpartum Hemorrhage
#DrugCompanyPhaseTrials
1Cytotec
PfizerApproved
Pitocin
RRetrophin
Approved
Cyklokapron
JJ Molner
Approved
Pabal
AACADIA Pharmaceuticals Inc.
Phase 3
IV Oxytocin
GSKPhase 3
Blood
UUniversity Hospital, Lille
Preclinical
Calcium Gluconate
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
I.V Oxytocin administration
BBezmialem Vakif University
Preclinical
Misopristol
SSohag University
Preclinical
Ergometrine
CCairo University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Misoprostol1 trial
Randomization of Oxytocin, Oxytocin+Intrauterine Misoprostol and Carbetocin During C-section
Completed·—·N/A·NCT05083910·156 enrolled
Postpartum Hemorrhage1 trial
Efficacy of Four Different Treatment Regimes on Postpartum Hemorrhage
Completed·—·N/A·NCT05467462·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for I.V Oxytocin administration. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBezmialem Vakif University